Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu

BEIJING | CHINA

Partnering to deliver
global solutions
tailored to your unique needs

Transactions

Our corporate finance solutions are tailored to our clients’ strategic goals and delivered based on in depth expertise across a wide range of sectors globally. We have a strong track record, participating in 80 transactions and raising C$6.1 billion on behalf of our clients in Q1/231.2.

Filter our transactions* using the categories below:

Eleusis Therapeutics
Pending Completion

Eleusis Therapeutics

Exclusive Financial Advisor (Sell side)
HEALTHCARE M&A ADVISORY US UK
View transaction detail
Nox Health
November 2022

Nox Health

Exclusive Financial Advisor (Sell side)
HEALTHCARE FINANCIAL SPONSORS M&A ADVISORY US
View transaction detail
Privia Health
US$117.5m
November 2022

Privia Health

Passive Bookrunner (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Natera
US$400m
November 2022

Natera

Co-Manager (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Akero Therapeutics, Inc.
US$230m
September 2022

Akero Therapeutics, Inc.

Lead Manager (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Aytu BioPharma
US$10m
August 2022

Aytu BioPharma

Joint Bookrunner (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
TransMedics Group, Inc.
US$130m
August 2022

TransMedics Group, Inc.

Lead Manager (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Sound Healthcare Communications
August 2022

Sound Healthcare Communications

Financial Advisor to Sound Healthcare Communications on its Sale to Medical Knowledge Group
TECHNOLOGY HEALTHCARE M&A ADVISORY US
View transaction detail
Biorez, Inc.
August 2022

Biorez, Inc.

Financial Advisor (Sell side)
HEALTHCARE M&A ADVISORY US
View transaction detail
Amplifire
July 2022

Amplifire

Canaccord Genuity Advises Amplifire, a Portfolio Company of Leeds Equity Partners, on its Significant Strategic Investment from Polaris Growth Fund
HEALTHCARE TECHNOLOGY FINANCIAL SPONSORS M&A ADVISORY US
View transaction detail
Stratasan
July 2022

Stratasan

Exclusive Financial Advisor (Sell side)
HEALTHCARE M&A ADVISORY FINANCIAL SPONSORS US
View transaction detail
Oncolytics Biotech
US$65m
June 2022

Oncolytics Biotech

Agent (ATM Offering)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
  1. Company information as of June 30, 2022
  2. Transactions valued above C$1.5 million

* Transactions displayed here include transactions of Canaccord Genuity and its predecessors. The logos used in the tombstones represent Canaccord Genuity’s clients unless otherwise specified in the transaction description

How can we help?

If you would like to find out more about Canaccord Genuity or any of our services, please get in touch.